Targeting Rare and Chronic Kidney Diseases

Tom Frohlich, chief operating officer of Chinook Therapeutics, about rare kidney diseases, the company’s lead therapeutic candidate atrasentan for IgA nephropathy, and the company’s plans for commercialization.